China Resources Double-Crane Pharmaceutical (SHA:600062) is planning to purchase low-risk bank financial products using idle funds to improve capital efficiency and generate additional investment income.
The company is planning to invest up to 500 million yuan, according to a Friday filing with the Shanghai bourse.
Shares of the pharmaceutical company rose 1% in recent trade.